Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.
FDA approval will help, as will insurer adoption of Galleri, but the price that they might be willing to pay for the test is also critical.
Grail (NASDAQ: GRAL) stock surged to a 12-month high following its FDA panel win, but investors should be wary of certain risks. The company's Molecular and Clinical Genetics Devices Panel voted in favor of Galleri's safety, benefit, and effectiveness, paving the way for FDA marketing approval. While this is a significant milestone, another crucial factor to consider is Grail's pricing strategy.
The company's binary event of FDA approval and medical insurer coverage has garnered most of the attention, but the pricing of its multi-cancer early detection test could impact its long-term success and investor returns.
Brief written by urgent.news from Motley Fool's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
